{
    "nctId": "NCT03162289",
    "briefTitle": "Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers",
    "officialTitle": "Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers - a Randomized, Controlled, Two-armed Intervention Study",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "FACT-G",
    "eligibilityCriteria": "Diagnosed, gynecological, malignant tumor disease (non-metastatic ovarian or breast cancer).\n\nOther inclusion criteria:\n\n* Age 18-75 years\n* Cancer is treated conventionally with an adjuvant or neo-adjuvant protocol with at least 4 CT cycles\n\nThe following CTs are considered for breast carcinoma:\n\n* - (EC, Sparano) 4 x Epirubicin and Cyclophosphamide, followed by 12 cycles Paclitaxel weekly\n* - (AC, Henderson) 4 x Doxorubicin, cyclophosphamide, followed by 4 cycles Docetaxel every three weeks\n\nIf the recruitment rate is not reached, further CT protocols can be accepted.\n\nCT for patients with ovarian cancer: According to current protocols, at least 4 planned cycles. For the study a maximum of 8 cycles are considered (except therapy with Taxol).\n\nExclusion Criteria:\n\n* Reduction in CT dose compared to usual dosage\n* Excessive underweight (BMI \\<19kg / m2) or actual weight reduction \\> 3kg or \\> 5kg in the last 1 or 3 months.\n* Pre-existing eating disorder (Anorexia nervosa, Bulimia)\n* Renal insufficiency (creatinine\\> 2mg / dl)\n* Severe disease or other disease with a significant reduction in mobility and overall vitality\n* Diabetes mellitus\n* No inclusion in other study protocol\n* Lack of email address and Internet access (due to electronic CRF)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}